Navigation Links
GeneNews appoints Canadian Colorectal Cancer Advisory Board
Date:11/19/2008

p>

Dr. Jeffrey Baker

Dr. Baker has been at St. Michael's Hospital since 1985 where he currently practices general gastroenterology with major interests in endoscopy, especially colonoscopy, inflammatory bowel disease and clinical nutrition. Dr. Baker graduated from the University of Toronto medical school and subsequently trained in internal medicine in Toronto and then gastroenterology at the Scripps Clinic and Research Foundation in La Jolla, California.

Dr. Khursheed Jeejeebhoy

Dr. Jeejeebhoy was the former division director of gastroenterology at the University of Toronto and the Toronto General Hospital and currently directs nutrition support and is a staff physician at St. Michael's Hospital. He is also a Emeritus Professor of Medicine, cross appointed to the Department of Nutritional Sciences at the University of Toronto. Dr. Jeejeebhoy received his medical degree from the Christian Medical College Hospital in Vellore, India and obtained his PhD from London University.

Dr. Andy Smith

Dr. Smith is a Surgical Oncologist at the Odette Cancer Centre, Head of the Division of General Surgery at Sunnybrook Health Sciences Centre and an Associate Professor at the University of Toronto. Dr. Smith completed medical school and General Surgery residency at the University of Toronto. During residency, he completed a Masters of Science studying the molecular biology of colorectal cancer.

Mr. Barry Stein

Mr. Stein is the President of the Colorectal Cancer Association of Canada (CCAC) and a survivor of metastatic colorectal cancer that was diagnosed in 1995. Mr. Stein graduated from McGill University faculties of Business Management and Law and he has been a member of the Bar of Quebec since 1981.

About GeneNews


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. GeneNews restructures operations
2. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
3. GeneNews Announces Second Quarter Results
4. GeneNews launches worlds first blood test for colorectal cancer screening
5. GeneNews announces management changes to support commercialization of ColonSentry(TM)
6. Genenews adds two members to its Board of Directors
7. GeneNews Announces First Quarter Results
8. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
9. GeneNews announces 2007 year end results
10. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
11. GeneNews receives ISO 13485 accreditation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...OOK, N.Y., Nov. 6 BioSpe...harmaceutical company developing first-in-class co...ncial results for the third quarter ended Septembe...in September of this year, the FDA,s Arthritis Adv... of 12-0, the approval of XIAFLEX(TM) for the trea...
(Date:11/6/2009)...IENNA, Austria, November 6 EUCODIS...nufacturing, and marketing enzymes for the,chemica...o a research,agreement with Bio Sidus, the leading..., The agreement gives EUCODIS Bioscience exclu...t - to Bio Sidus, proprietary collection of,psychr...
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ORTATION -- Gone hybrid . . . , Fuel economy r... now posted at the www.fueleconomy.gov web site,... maintains for the U.S. Department of Energy and t...he top 10 vehicles on the best fuel economy list a...PG city; 48 highway). "This list proves that hybri...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3
...ent Response to Novel Beta Blocker ...dolol, an investigational,pharmacologically unique...reduces hospitalization and death among heart fail...ing to results of a large DNA study presented,toda...ailure Society of,America. Researchers found that ...
...US$10 million received based on the positive revie...ultiple sclerosis trial - EDMONTON, Sept. 22 /PRN..., a leading developer in the treatment of multiple...ved the US$10 million milestone payment from its,p...ment is based on the previously announced positive...
...l Systems and BrainLAB enabling, non-invasive tr...vous system, PALO...ctors around the globe are turning more and,more t... for the treatment,of cancer and other conditions.... Systems (NYSE: VAR ) and BrainLAB, doctors are p...
Other Biology Technology:Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 2Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
(Date:11/4/2009)...HILADELPHIA Although scientists are reluctant to ...n method, evidence continues to grow about its pro...published in Cancer Prevention Research , a journ..., which suggests some reduction in oral cancer. ,...f medicine in the Department of Thoracic/Head and ...
(Date:11/4/2009)...eavy traffic corridors in the cities of Long Beach...roportion of preventable childhood asthma, and the...n the disease has likely been underestimated, acco... California (USC). , The study, which appears i...blic Health , estimated that nine percent of all c...
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 1AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 3
...ug development : only "lucrative","markets" get ex...ve,seen very promising drugs candidates or related...de with it, even if millions would have,been saved...is to find,a drug candidate that affect a "profita...ne. PLoS Medecine has an article about a possible,...
...f the Chinese hybrid rice genome, which was publis...s have recently finished the fine map of the rice ...e of PLoS Biology (Vol.3 Issue 2, 2005), scientist...eported a "much improved, near-complete genome ana...sativa." , The fine maps of the rice genome seque...
...lar signaling mechanism whose existence has been,k...since the,identification of a mutant strain of Dro...Hunt Morgan’s lab in 1910. Later studies,revealed ...t extends,through both sides of the cell membrane ...partner, such as the protein Delta, presented,on t...
Other Biology News:Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Whole genome fine map of rice completed 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
Anti-Endomorphin-2 Polyclonal Antibody, Unconjugated from CHEMICON
...0kb), and large plasmid insert (10-20kb) DNAs. Gre... command 20-50 fold copy amplification for high yi...ble with blue-white screening (pEZ BAC) or transcr...sert stability. Kits include electrocompetent cell...
PCRX Enhancer System from Invitrogen
Goat Anti-MAGP-2 (C-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: